Carcinoma, Squamous Cell* / diagnostic imaging ; Carcinoma, Squamous Cell* / pathology ; Female ; Fluorodeoxyglucose F19 ; Head and Neck Neoplasms* ; Human Papillomavirus Viruses ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Papillomavirus Infections* / diagnostic imaging ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck
Keywords
Positron emission tomography computed tomography ; human papillomavirus ; magnetic resonance imaging ; oropharyngeal cancer
Abstract
Purpose: Predicting human papillomavirus (HPV) status is critical in oropharyngeal squamous cell carcinoma (OPSCC) ra diomics. In this study, we developed a model for HPV status prediction using magnetic resonance imaging (MRI) radiomics and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) parameters in patients with OPSCC.
Materials and Methods: Patients with OPSCC who underwent 18F-FDG PET/CT and contrast-enhanced MRI before treatment between January 2012 and February 2020 were enrolled. Training and test sets (3:2) were randomly selected. 18F-FDG PET/CT parameters and MRI radiomics feature were extracted. We developed three light-gradient boosting machine prediction models using the training set: Model 1, MRI radiomics features; Model 2,18F-FDG PET/CT parameters; and Model 3, combination of MRI radiomics features and 18F-FDG PET/CT parameters. Area under the receiver operating characteristic curve (AUROC) values were used to analyze the performance of the models in predicting HPV status in the test set.
Results: A total of 126 patients (118 male and 8 female; mean age: 60 years) were included. Of these, 103 patients (81.7%) were HPV-positive, and 23 patients (18.3%) were HPV-negative. AUROC values in the test set were 0.762 [95% confidence interval (CI), 0.564–0.959], 0.638 (95% CI, 0.404–0.871), and 0.823 (95% CI, 0.668–0.978) for Models 1, 2, and 3, respectively. The net reclassifica tion improvement of Model 3, compared with that of Model 1, in the test set was 0.119.
Conclusion: When combined with an MRI radiomics model, 18F-FDG PET/CT exhibits incremental value in predicting HPV sta tus in patients with OPSCC.